Active ingredientZandelisibCat. No. P-Z006-001CAS 1401436-95-0Family · Pharmaceutical analytical standards
Zandelisib
An investigational PI3K delta inhibitor, studied against indolent B-cell lymphomas such as follicular lymphoma and marginal zone lymphoma; in December 2022 development was stopped outside Japan. This family brings together the active ingredient.
Did you know?Its name ends in -lisib, like those of almost all phosphatidylinositol 3-kinase (PI3K) inhibitors, for example idelalisib and duvelisib: a suffix they share.
Go to the active ingredient →Active ingredientZandelisibCat. No. P-Z006-001CAS 1401436-95-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.